Phase 2 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with POEMS syndrome, confirmed using the 2023 Dispenzieri diagnostic criteria
- People aged between 18 and 75 years
- People who are reasonably mobile and able to carry out basic daily activities, with a life expectancy of more than 3 months (confirm with trial site regarding specific activity scale used)
- People who do not currently have an active infection
- People who have not previously received any treatment specifically for POEMS syndrome, other than corticosteroids (a type of anti-inflammatory medication)
- People whose heart, liver, and kidneys are functioning well enough to meet specific laboratory test thresholds set by the trial
- People whose blood count results — including white blood cells, platelets, and haemoglobin — meet the minimum levels required by the trial, without recent reliance on blood transfusions or growth factor medications
- People who are able to swallow and take medications by mouth
- People who have completed all required screening tests and assessments as outlined in the study
- People who have signed a consent form agreeing to take part in chemotherapy as part of the trial
Who may not be able to join:
- People whose POEMS syndrome also involves multiple myeloma, light chain amyloidosis, or a condition called Waldenström macroglobulinemia
- People who are HIV-positive, or who have active hepatitis A, B, or C infection, or certain elevated hepatitis B virus levels in their blood
- People who have serious ongoing health conditions such as heart failure, kidney failure, liver failure, bleeding disorders, a blood clot event within the past 6 months, uncontrolled diabetes, or a history of a specific type of bladder inflammation
- People who have had an autoimmune disease (such as Crohn's disease, rheumatoid arthritis, or lupus) within the past 2 years that caused organ damage or needed ongoing medication to control it
- People with severe active infections such as untreated tuberculosis or a serious fungal lung infection
- People who currently have another type of cancer, with some exceptions for certain early-stage or previously cured cancers (confirm with trial site for specific exceptions)
- People with epilepsy requiring medication, dementia, or other conditions affecting mental function that would make it difficult to understand or follow the study requirements
- People whose circumstances — including substance use, psychological, or social factors — may interfere with participation or the reliability of study results
- People who are pregnant or breastfeeding
- People who the trial investigator considers unsuitable for the trial for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Haiyan He, Dr., Shanghai Changzheng Hospital
Phone: +86 13661513012
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall hematological response rate; Overall VEGF response rate; Overall neurological response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.